Recent research into modern breast cancer therapies have driven major breakthroughs in antibody-drug conjugates, or “smart drugs,” which work by targeting cancer cells while minimizing damage to healthy body tissue.
Kadcyla, also known ado-trastuzumab emtansine (T-DM1), is one of the latest “smart drugs” to be FDA-approved in the treatment of women diagnosed with metastatic HER2-positive breast cancer. Kadcyla may also have potential as therapy after surgery where intent is curative.
Breastlink participated in the EMILIA trial, a key clinical trial that helped lead to swift approval of Kadcyla for HER2-positive advanced breast cancer. We also are participating in other ongoing trials to investigate additional uses for Kadcyla in HER2 […]